BTS
CLDX icon

BB&T Securities’s Celldex Therapeutics CLDX Stock Holding History

BB&T Securities’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-3,133
Closed -$9K – 1613
2018
Q4 		$9K Hold
3,133
– – ﹤0.01% 1472
2018
Q3 		$21K Hold
3,133
– – ﹤0.01% 1568
2018
Q2 		$23K Hold
3,133
– – ﹤0.01% 1527
2018
Q1 		$109K Sell
3,133
-4
-0.1% -$155 ﹤0.01% 1456
2017
Q4 		$133K Sell
3,137
-40
-1% -$1.71K ﹤0.01% 1394
2017
Q3 		$136K Hold
3,177
– – ﹤0.01% 1344
2017
Q2 		$117K Buy
+3,177
New +$141K ﹤0.01% 1343

Other funds holding CLDX

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
TCMG
TSP Capital Management Group Summit, New Jersey $418M AUM 68.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

BB&T Securities's CLDX Position: Q1 2019 in Review

BB&T Securities sold out of Celldex Therapeutics (CLDX) in Q1 2019, closing a stake of 3,133 shares — an estimated $9K sold.

BB&T Securities first reported a position in CLDX in Q2 2017 and held it in 7 quarters. The position peaked at $136K in Q3 2017. 53 funds tracked by Wall St. Rank hold CLDX as of Q1 2019.

  • BB&T Securities reported no remaining Celldex Therapeutics position as of Q1 2019 after selling out during the quarter.
  • BB&T Securities sold 3,133 Celldex Therapeutics shares in Q1 2019, an estimated $9K.
  • BB&T Securities first reported a position in Celldex Therapeutics in Q2 2017 and held it in 7 quarters.
  • BB&T Securities's Celldex Therapeutics position peaked at $136K in Q3 2017.
  • 53 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2019.

Based on BB&T Securities's 13F filing for Q1 2019, filed 14 May 2019.